Physician profile
George Carr
NPI 1528032661
$24,635.93
in general payments reported to CMS, 2019-2025
71 companies · $3,093 in 2025
The $3,093 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,707 · 2020: $1,322 · 2021: $1,918 · 2022: $2,400 · 2023: $2,574 · 2024: $4,623 · 2025: $3,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,590 · Travel and Lodging: $1,563 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,589.96 |
| Travel and Lodging | $1,562.94 |
| Education | $135.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $7,293.03 | 2019-2022 | |
| Abbvie INC. | $2,511.02 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Medtronic, INC. | $2,074.07 | 2022-2025 | Interstim, Intellis Adaptivestim, Na |
| Pfizer INC. | $1,782.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,275.29 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,215.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $666.50 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $645.99 | 2019-2025 | Mounjaro, Zepbound, Reyvow |
| Bayer Healthcare Pharmaceuticals INC. | $616.52 | 2022-2025 | |
| Abbott Laboratories | $591.35 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Glaxosmithkline, LLC. | $395.96 | 2019-2025 | Shingrix, Arexvy, Nucala |
| Merck Sharp & Dohme LLC | $367.96 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.60 | 2019-2025 | Trulance, Xifaxan |
| Allergan, INC. | $321.87 | 2019-2020 | |
| Amarin Pharma, INC. | $307.45 | 2019-2022 |
Show all 66 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.